The Tübingen biotech company Curevac is still in the red because of the withdrawal of its first vaccine candidate. The operating loss last year was 412.3 million euros (2020: 109.8 million euros). According to the company, the increase in research and development expenditure is primarily due to significantly higher costs from the then approval-relevant 2b/3 study phase with 40,000 test persons. Losses before taxes amounted to EUR 412.5 million in the 2021 financial year (2020: EUR 129.8 million). Sales rose to 103.0 million euros last year after 48.9 million euros in 2020. According to CFO Pierre Kemula, most of the obligations due to the withdrawal of the first vaccine candidate have now been resolved. “It is important that we have received confirmation from the European Union that the 450 million prepayment for CVnCoV does not have to be repaid.” Curevac started a clinical study of its new vaccine candidate (CV2CoV) against Corona at the end of March. After CVnCoV withdrew due to weak effectiveness, Curevac and its British partner – the pharmaceutical company GlaxoSmithKline (GSK) – began developing a new vaccine.
Biotech company – Curevac makes a loss – Economy
